Related Experiment Videos
Kidney transplantation and malignant diseases.
T Grosmanová1, M Tomsu, K Konecný
11st Clinic of Surgery, Medical Faculty, Palacký University, Olomouc, Czechoslovakia.
Acta Universitatis Palackianae Olomucensis Facultatis Medicae
|January 1, 1991
Summary
Kidney transplant recipients have a fivefold higher cancer risk. Early cancer detection and treatment in these patients significantly improve survival, highlighting the importance of oncologic follow-up.
Area of Science:
- Nephrology
- Oncology
- Transplantation Medicine
Background:
- Kidney transplant recipients face an elevated risk of developing malignancies.
- Cancer incidence post-transplantation is a critical concern for long-term patient outcomes.
Purpose of the Study:
- To determine the incidence of malignant diseases in kidney transplant patients.
- To analyze the impact of immunosuppression protocols on tumor development timelines.
- To identify common cancer sites and evaluate survival rates after diagnosis.
Main Methods:
- Retrospective analysis of patient data using three types of questionnaires.
- Documentation of all registered tumors in kidney transplant recipients.
- Comparison of tumor incidence with the general population.
Main Results:
- 34 tumors were registered in kidney transplant patients.
- Cancer incidence was five times higher than in the standard population.
- Mean time to tumor formation decreased from 48 months (classical immunosuppression) to 19 months (cyclosporine).
- Skin and kidney were the most frequent sites for tumors.
- Early diagnosis and surgical treatment increased survival to 58 months.
Conclusions:
- Kidney transplant patients exhibit a significantly higher risk of developing malignancies.
- Immunosuppression, particularly cyclosporine, influences the timing of tumor development.
- Systematic oncologic follow-up and preventive measures are crucial for improving survival and graft function in transplant recipients.